Abstract
Background:
No licensed vaccine is currently available against serotype A foot-and-mouth disease (FMD) in China, despite the isolation of A/WH/CHA/09 in 2009, partly because this strain does not replicate well in baby hamster kidney (BHK) cells.
Methodology/principal findings:
A novel plasmid-based reverse genetics system was used to construct a chimeric strain by replacing the P1 gene in the vaccine strain O/CHA/99 with that from the epidemic stain A/WH/CHA/09. The chimeric virus displayed growth kinetics similar to those of O/CHA/99 and was selected for use as a candidate vaccine strain after 12 passages in BHK cells. Cattle were vaccinated with the inactivated vaccine and humoral immune responses were induced in most of the animals on day 7. A challenge infection with A/WH/CHA/09 on day 28 indicated that the group given a 4-µg dose was fully protected and neither developed viremia nor seroconverted to a 3ABC antigen.
Conclusions/significance:
Our data demonstrate that the chimeric virus not only propagates well in BHK cells and has excellent antigenic matching against serotype A FMD, but is also a potential marker vaccine to distinguish infection from vaccination. These results suggest that reverse genetics technology is a useful tool for engineering vaccines for the prevention and control of FMD.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antibodies, Neutralizing / blood
-
Antibodies, Neutralizing / immunology
-
Antibodies, Viral / blood
-
Antibodies, Viral / immunology
-
Cattle
-
Cattle Diseases / immunology*
-
Cattle Diseases / prevention & control
-
Cell Line
-
Cricetinae
-
Foot-and-Mouth Disease / immunology*
-
Foot-and-Mouth Disease / prevention & control
-
Foot-and-Mouth Disease Virus / genetics*
-
Foot-and-Mouth Disease Virus / growth & development
-
Foot-and-Mouth Disease Virus / immunology*
-
Gene Order
-
Mice
-
Plasmids / genetics
-
RNA, Viral / genetics
-
Vaccines, Inactivated / administration & dosage
-
Vaccines, Inactivated / genetics
-
Vaccines, Inactivated / immunology
-
Viral Vaccines / administration & dosage
-
Viral Vaccines / genetics*
-
Viral Vaccines / immunology*
Substances
-
Antibodies, Neutralizing
-
Antibodies, Viral
-
RNA, Viral
-
Vaccines, Inactivated
-
Viral Vaccines
Grants and funding
This work was supported by grants from the National High Technology Research and Development Program of China (863 Program) (2011AA10A211-1), the High-level Technological Talent Program of Gansu province (1013JHTA008), the China Agriculture Research System (CARS-39), the International Atomic Energy Agency (16025/R0), and the EPIZONE (FOOD-CT-2006-016236) project. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.